Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says

12/02/2021 | 10:38pm EST


© MT Newswires 2021
All news about PFIZER, INC.
01/24Pfizer Urged To Ramp Up COVID-19 Pill Supply In Developing Countries, Aid Generics Entr..
MT
01/24Britain says 6,000 more people needed for trial of Merck COVID pill
RE
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
01/24Kids' vaccine rate still low despite rampant spread of Omicron variant
AQ
01/24Health Care Stocks Declining This Afternoon
MT
01/24Health Care Stocks Dragged Lower in Broad-Based Equities Selloff
MT
01/24Chile to purchase 2 million Moderna COVID-19 vaccine doses
RE
01/24Advocacy group urges Pfizer to sell more COVID pills to developing countries
RE
01/24EU Drug Regulator Reportedly Will Decide on Approval of Pfizer's COVID-19 Pill by End o..
MT
01/24Anixa Biosciences Says New COVID-19 Compound Shows Promise in Preliminary Lab Test
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 839 M - -
Net income 2021 22 216 M - -
Net Debt 2021 27 401 M - -
P/E ratio 2021 13,5x
Yield 2021 3,08%
Capitalization 289 B 289 B -
EV / Sales 2021 3,87x
EV / Sales 2022 2,98x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 51,54 $
Average target price 57,88 $
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-12.72%289 287
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963
NOVO NORDISK A/S-17.16%210 749